Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.

[1]  Zuben E Sauna,et al.  Fc fusion as a platform technology: potential for modulating immunogenicity. , 2015, Trends in biotechnology.

[2]  Liping Zhao,et al.  A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice. , 2014, Molecular immunology.

[3]  Elena Stylianou,et al.  Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG. , 2014, Plant biotechnology journal.

[4]  Hongjuan Yu,et al.  Subunit Vaccine Consisting of Multi-Stage Antigens Has High Protective Efficacy against Mycobacterium tuberculosis Infection in Mice , 2013, PloS one.

[5]  H. McShane,et al.  Vaccination against tuberculosis: how can we better BCG? , 2013, Microbial pathogenesis.

[6]  Zhifeng Shao,et al.  Fc-fusion proteins: new developments and future perspectives , 2012, EMBO molecular medicine.

[7]  A. Izzo,et al.  HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule , 2012, Immunology and cell biology.

[8]  Shuliang Guo,et al.  Immunotherapy for tuberculosis: what's the better choice? , 2012, Frontiers in bioscience.

[9]  Jianfeng He,et al.  Polymeric human Fc-fusion proteins with modified effector functions , 2011, Scientific reports.

[10]  S. Thomson,et al.  Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis. , 2011, Vaccine.

[11]  D. Roopenian,et al.  A Neonatal Fc Receptor-Targeted Mucosal Vaccine Strategy Effectively Induces HIV-1 Antigen-Specific Immunity to Genital Infection , 2011, Journal of Virology.

[12]  Steven B. Bradfute,et al.  Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. , 2011, Vaccine.

[13]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[14]  C. Colaco,et al.  Adjuvant-Free Immunization with Hemagglutinin-Fc Fusion Proteins as an Approach to Influenza Vaccines , 2010, Journal of Virology.

[15]  H. Zhang,et al.  Recombinant Mycobacterium smegmatis Expressing an ESAT6‐CFP10 Fusion Protein Induces Anti‐Mycobacterial Immune Responses and Protects Against Mycobacterium tuberculosis Challenge in Mice , 2010, Scandinavian journal of immunology.

[16]  S. Nakae,et al.  Essential Role of IL-17A in the Formation of a Mycobacterial Infection-Induced Granuloma in the Lung , 2010, The Journal of Immunology.

[17]  Yvonne Perrie,et al.  Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Y. Belkaid,et al.  Regulatory T cells in the control of host-microorganism interactions (*). , 2009, Annual review of immunology.

[19]  M. Paul,et al.  Cytokine therapy of tuberculosis at the crossroads , 2009, Expert review of respiratory medicine.

[20]  P. Andersen,et al.  Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements , 2008, PloS one.

[21]  Y. Li,et al.  Utilization of Fc Receptors as a Mucosal Vaccine Strategy against an Intracellular Bacterium, Francisella tularensis1 , 2008, The Journal of Immunology.

[22]  J. Andersen,et al.  Dependence of antibody-mediated presentation of antigen on FcRn , 2008, Proceedings of the National Academy of Sciences.

[23]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2007, Current protocols in protein science.

[24]  J. Keane,et al.  T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. , 2007, Immunity.

[25]  M. Palmer,et al.  An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis. , 2007, Vaccine.

[26]  Pingzuo Li,et al.  Expression of Recombinant Proteins in Pichia Pastoris , 2007, Applied biochemistry and biotechnology.

[27]  Kamlesh Bhatt,et al.  Host Innate Immune Response to Mycobacterium tuberculosis , 2007, Journal of Clinical Immunology.

[28]  M. Barbouche,et al.  High level expression of recombinant Mycobacterium tuberculosis culture filtrate protein CFP32 in Pichia pastoris , 2007, Molecular biotechnology.

[29]  J. Flynn,et al.  IL-17 Production Is Dominated by γδ T Cells rather than CD4 T Cells during Mycobacterium tuberculosis Infection1 , 2006, The Journal of Immunology.

[30]  S. Khader,et al.  IL-23 Compensates for the Absence of IL-12p70 and Is Essential for the IL-17 Response during Tuberculosis but Is Dispensable for Protection and Antigen-Specific IFN-γ Responses if IL-12p70 Is Available1 , 2005, The Journal of Immunology.

[31]  A. Sher,et al.  Maintenance of Pulmonary Th1 Effector Function in Chronic Tuberculosis Requires Persistent IL-12 Production , 2005, The Journal of Immunology.

[32]  R. Graziano,et al.  Enhanced Antigen-Specific Antibody and Cytokine Responses When Targeting Antigen to Human FcGAMMA Receptor Type I Using an Anti-Human FcGAMMA Receptor Type I-Streptavidin Fusion Protein in an Adjuvant-Free System , 2005, Immunological investigations.

[33]  A. Rao,et al.  An epigenetic view of helper T cell differentiation , 2003, Nature Immunology.

[34]  G. Kollias,et al.  Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. , 2003, Immunity.

[35]  Ian W. Davis,et al.  Structure validation by Cα geometry: ϕ,ψ and Cβ deviation , 2003, Proteins.

[36]  S. Reed,et al.  Prospects for a better vaccine against tuberculosis. , 2003, Tuberculosis.

[37]  Andrew L. Kung,et al.  Role of T-bet in Commitment of TH1 Cells Before IL-12-Dependent Selection , 2001, Science.

[38]  L. Vitale,et al.  Targeting Weak Antigens to CD64 Elicits Potent Humoral Responses in Human CD64 Transgenic Mice , 2000, The Journal of Immunology.

[39]  T. Ottenhoff,et al.  Antigenic Equivalence of Human T-Cell Responses toMycobacterium tuberculosis-Specific RD1-Encoded Protein Antigens ESAT-6 and Culture Filtrate Protein 10 and to Mixtures of Synthetic Peptides , 2000, Infection and Immunity.

[40]  B. Heyman,et al.  Regulation of antibody responses via antibodies, complement, and Fc receptors. , 2000, Annual review of immunology.

[41]  B. Gicquel,et al.  A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). , 1998, Microbiology.

[42]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[43]  P. Wallace,et al.  Increased potency of Fc-receptor-targeted antigens , 1997, Cancer Immunology, Immunotherapy.

[44]  S. Mjaaland,et al.  Comparing macrophages and dendritic leukocytes as antigen‐presenting cells for humoral responses in vivo by antigen targeting , 1994, European journal of immunology.

[45]  A. Lanzavecchia.  Identifying strategies for immune intervention. , 1993, Science.

[46]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[47]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[48]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.